Abstract
Hemophilia A is an autosomal recessive X-linked deficiency of factor VIII. Because of the mode of transmission and gene expression, males have hemophilia A, and females are usually asymptomatic carriers of the hemophilia A gene. All daughters of a hemophiliac father are carriers of the hemophilia A gene; all his sons are normal. The children of a female hemophilia A carrier have a 50% chance of being affected by the gene. Hemophilia A affects approximately 1 in 10,000 to 20,000 males in the United States.1
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Monsour PA, Kruger B J, Harden PA. Prevalence and detection of patients with bleeding disorders. Aust Dent J 1986;31:104–11.
Aronstom A. Hemophilic bleeding. East Sussex, UK: Balliere Tindall, 1985.
Williams WJ, Beutler E, Erslev AJ, Lichtman MA. Hematology. New York: McGraw-Hill, 1990.
Mannucci PM. Desmopressin (DDAVP) for treatment of hemophilia. Prog Hemost Thromb 1986;8:19–45.
Colleen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980;43:77–89.
Brocker-Vriende AJHT, Briët E, Quadt R. Genotype assignment of haemophilia A by use of intragenic and extragenic restriction fragment length polymorphisms. Thromb Haemost 1987;57:131–6.
Graham JB, Green PP, McGraw RA, Davis LM. Application of molecular genetics to prenatal diagnosis and carrier detection in the hemophilias: some limitations. Blood 1985;66:759–64.
Leahey M, Wright LM. Intervening with families with chronic illness. Farn Syst Med 1985;3:60–9.
Bowie EJW, Didisheim P, Thompson JH, Owen CA. von Willebrand’s disease: a critical review. Hematol Rev 1968;1:1–50.
Ngo KY, Glotz VT, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988;85:2753–7.
Batlle J, Fernanda M, Lopez-Fernandez F, et al. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. Blood 1987;70:173–6.
Harrison RL, McKee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 1984;63:657–65.
Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985;228: 1401–6.
Bertina RM, Van Der Marel-Van Nieuwkoop W, Dubbeldam J, Boekhout-Mussert RJ, Veitkamp JJ. New method for the rapid detection of vitamin K deficiency. Clin Chim Acta 1980;105:93–8.
Committee on Nutrition. Vitamin K supplementation for infants receiving milk substitute infant formulas and for those with fat malabsorption. Pediatrics 1971;48:483–6.
Lusher JM, Iyer R. Ideopathic thrombocytopenic purpura in children. Semin Thromb Hemost 1977;3:175–99.
DiFino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy. Am J Med 1980;69:430–42.
McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981;304:1135–47.
Akwari OE, Itani KMF, Coleman RE, Rosse WF. Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP): current criteria for patient selection and results. Ann Surg 1987;206:529–39.
Nalli G, Sajeva R, Carnevale MG, Ascari E. Ranazol therapy for ideopathic thrombocytopenic purpura (ITP). Haematologica 1988; 73:55–7.
Awidi AS, El-Khateeb MS, Abu Khalaf MM, Tarawneh MS, Shannak MS. A controlled trial of steroids and splenectomy versus bolus intravenous vincristine in the treatment of adult idiopathic thrombocytopenic purpura. Curr Ther Res 1986;40:809–13.
Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987;52:206–11.
Blanchette VS, Hogan VA, McCombie NE, et al. Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura. Transfusion 1984;24:388–94.
Strother SV, Zuckerman KS, LoBuglio AF. Colchicine therapy for refractory idiopathic thrombocytopenic purpura. Arch Intern Med 1984;144:2198–2200.
Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc receptor antibody. N Engl J Med 1986;314:1236–9.
Bird RM, Hammarsten JF, Marshall RA, Robinson RR. A study of hereditary hemorrhagic telangiectonia. N Engl J Med 1957;257: 105–9.
Bird RM, Jaques WE. Vascular lesion of hereditary hemorrhagic telangiestasia. N Engl J Med 1959;260:597–9.
Tattersall RN, Seville R. purpura. Q J Med 1950;19:151–9.
Levinsky RJ, Barratt TM. IgA immune complexes in Henoch-Schonlein purpura. Lancet 1979;2 (8152):1100–3.
Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children (Schonlein-Henoch syndrome): review with a follow-up of the renal complications. AMA J Dis Child 1960;99:833–54.
Kugelman IN. Cortisone in allergic purpura of children. NY State J Med 1951;51:2504–6.
Szelid Z, Bereczky J, Nagymanyai Z, Ruszinhow V. Heparin prophylaxis of Henoch-Schonlein nephropathy. Acta Paediatr Hung 1986;27:57–60.
Lackner H, Karpatkin S. On the “easy bruising“ syndrome with normal platelet count: a study of 75 patients. Ann Intern Med 1975;83:190–6.
Coleman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation: a reappraisal. Annu Rev Med 1979;30:359–74.
Coleman RW, Robboy S J, Minna JD. Disseminated intravascular coagulation (DIC): an approach. Am J Med 1972;52:679–89.
Williams WJ, Beutler E, Erslen AJ, Lichtman MA. Hematology. New York: McGraw-Hill, 1990.
Shoenfeld Y, Modan M, Berliner S, et al. The mechanism of benign hereditary neutropenia. Arch Intern Med 1982;April(4):142;797–9.
Dale DC, Guerry D, Wewerka JR, Bull JM, Chusid MJ. Chronic neutropenia. Medicine (Baltimore) 1979;58:128–44.
Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987;66:337–40.
Pincus SH, Boxer LA, Stossel TP. Chronic neutropenia in childhood. Am J Med 1976;61:849–61.
Lakos A, Timar L. Treatment of idiopathic chronic neutropenia with high-dose intravenous immunoglobulin. Pediatr Forum 1987; 141:12–3.
Van der Veen JPW, Hack CE, Engelfriet CP, Pegels JG, von dem Borne AEG. Chronic idiopathic and secondary neutropenia: clinical and serological investigations. Br J Haematol 1986;63:161–71.
Conway LT, Clay ME, Kline WE, Ramsay NKC, Krivit W, McCullough J. Natural history of primary autoimmune neutropenia in infancy. Pediatrics 1987;79:728–33.
Bussel J, Lalezari P, Fikrig S. Intravenous treatment with gammaglobulin of autoimmune neutropenia of infancy. J Pediatr 1988;112:298–301.
Lalevari P, Murphy GB, Allen FH. NB1, a new neutrophil-specific antigen involved in the pathogenesis of neonatal neutropenia. J Clin Invest 1971;50:1108–15.
Minchinton RM, McGrath KM. Alloimmune neonatal neutropenia—a neglected diagnosis. Med J Aust 1987;147:139–41.
Dale DC, Hammond WP. Cyclic neutropenia: a clinical review. Blood Rev 1988;2:178–85.
Williams WJ, Beutler E, Erslev AV, Lichtner MA. Hematology. New York: McGraw-Hill, 1990.
Vadhan RS. Clinical applications of colony-stimulating factors. Oncol Nurs Forum 1989;16 (Suppl);21–6.
Modan B. An epidemiological study of polycythemia vera. Blood 1965;26:657–67.
Ramamurthy RS, Yves WB. Neonatal polycythemia: one criterion for diagnosis and treatment. Pediatrics 1981;68:168–74.
Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339–51.
Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1–12.
Yu TF. Secondary gout associated with myeloproliferative diseases. Arthritis Rheum 1965;8:765–71.
Brodsky I. Busulphan treatment of polycythemia vera. Br J Haematol 1982;52:1–6.
Dean J, Schechter AN. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches. N Engl J Med 1978;299:752–63.
Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med 1979;18:1001–5.
Dunston T, Rowland R, Huntsman RG, Yawson G. Sickle-cell haemoglobin C disease and sickle-cell beta thalassanemia in white South Africans. S Afr Med J 1972;46:1423–6.
Luzzatto L. Genetics of red cells and susceptibility to malaria. Blood 1979;54:961–76.
Boghossian SH, Wright G, Webster DB, Segal AW. Investigations of host defense in patients with sickle cell disease. Br J Haematol 1985;59:523–31.
Powars DR. Natural history of sickle cell disease—the first ten years. SeminHematol 1975;12:267–85.
Kark JA, Posey DM, Schumacher HR, Ruehle CJ. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med 1987;317:781–7.
Vermylen C, Robles EF, Ninane J, Cornu G. Bone marrow transplantation in five children with sickle cell anemia. Lancet 1988; 1: 1427–8.
Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990;320:1037–43.
Abraham DJ, Mehanna AS, Wireko FC, et al. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood 1991 ;77:1334–41.
Levitan M. Textbook of human genetics. 3rd ed. New York: Oxford University Press, 1988.
Penn P. Coalitions and binding interactions in families with chronic illness. Farn Syst Med 1983;1:16–25.
Leahey M, Wright LM. Interviewing with families with chronic disease. Farn Syst Med 1985;3:60–9.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Paulman, P.M., Wolf-Gillespie, N., Prest, L.A. (1994). Selected Disorders of the Blood and Hematopoietic System. In: Taylor, R.B. (eds) Family Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-4005-9_127
Download citation
DOI: https://doi.org/10.1007/978-1-4757-4005-9_127
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4757-4007-3
Online ISBN: 978-1-4757-4005-9
eBook Packages: Springer Book Archive